JP2024528682A5 - - Google Patents

Info

Publication number
JP2024528682A5
JP2024528682A5 JP2024503607A JP2024503607A JP2024528682A5 JP 2024528682 A5 JP2024528682 A5 JP 2024528682A5 JP 2024503607 A JP2024503607 A JP 2024503607A JP 2024503607 A JP2024503607 A JP 2024503607A JP 2024528682 A5 JP2024528682 A5 JP 2024528682A5
Authority
JP
Japan
Prior art keywords
seq
variable region
antibody
amino acid
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/107522 external-priority patent/WO2023001303A1/zh
Publication of JP2024528682A publication Critical patent/JP2024528682A/ja
Publication of JP2024528682A5 publication Critical patent/JP2024528682A5/ja
Pending legal-status Critical Current

Links

JP2024503607A 2021-07-23 2022-07-22 薬物組成物及び用途 Pending JP2024528682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110842497 2021-07-23
CN202110842497.1 2021-07-23
PCT/CN2022/107522 WO2023001303A1 (zh) 2021-07-23 2022-07-22 药物组合物及用途

Publications (2)

Publication Number Publication Date
JP2024528682A JP2024528682A (ja) 2024-07-30
JP2024528682A5 true JP2024528682A5 (enExample) 2026-06-08

Family

ID=84978972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503607A Pending JP2024528682A (ja) 2021-07-23 2022-07-22 薬物組成物及び用途

Country Status (11)

Country Link
US (1) US20240352153A1 (enExample)
EP (1) EP4375300A4 (enExample)
JP (1) JP2024528682A (enExample)
KR (1) KR20240038043A (enExample)
CN (1) CN116059341A (enExample)
AU (1) AU2022314097A1 (enExample)
CA (1) CA3226242A1 (enExample)
IL (1) IL310217A (enExample)
MX (1) MX2024001067A (enExample)
WO (1) WO2023001303A1 (enExample)
ZA (1) ZA202400787B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
KR20230098221A (ko) * 2020-10-26 2023-07-03 아케소 바이오파마, 인크. 항-tigit 항체, 약학 조성물 및 이의 용도
IL322840A (en) * 2023-02-20 2025-10-01 Akeso Biopharma Co Ltd Fusion protein comprising a TGF-βRII extracellular region fragment, its pharmaceutical composition and use
WO2025016012A1 (en) * 2023-07-14 2025-01-23 Genor Biopharma Co., Ltd. Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途
WO2025232896A1 (zh) * 2024-05-10 2025-11-13 康方汇科(上海)生物有限公司 药物组合及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
CN109384846B (zh) * 2018-09-25 2020-03-03 合肥瑞达免疫药物研究所有限公司 能够结合tigit的抗体或其抗原结合片段及用途
CN113573782B (zh) * 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
EP4008730A4 (en) 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2021093849A1 (en) * 2019-11-14 2021-05-20 Wuxi Biologics (Shanghai) Co., Ltd. A novel antibody against tigit
KR20230098221A (ko) * 2020-10-26 2023-07-03 아케소 바이오파마, 인크. 항-tigit 항체, 약학 조성물 및 이의 용도
CN112794909B (zh) * 2021-02-04 2022-06-14 广州爱思迈生物医药科技有限公司 一种抗tigit单克隆抗体及其应用
CN114106182B (zh) * 2022-01-26 2022-05-17 中山康方生物医药有限公司 抗tigit的抗体及其用途
CN114181310B (zh) * 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途

Similar Documents

Publication Publication Date Title
JP2023171775A5 (enExample)
JP2022184985A5 (enExample)
JP2023166402A5 (enExample)
JP2023103258A5 (enExample)
JP2021184963A5 (enExample)
JP2023145572A5 (enExample)
JP2024116190A5 (enExample)
JP2025511899A5 (enExample)
JP2023518821A5 (enExample)
JP2022541332A5 (enExample)
JP2025176106A5 (enExample)
JP2022543046A5 (enExample)
JP2022068302A5 (enExample)
JP2023514727A5 (enExample)
JP2023181322A5 (enExample)
JP2022538797A5 (enExample)
JP2023552816A5 (enExample)
JP2023022224A5 (enExample)
JP2024045126A5 (enExample)
JP2023100857A5 (enExample)
JP2025098156A5 (enExample)
JP2023093656A5 (enExample)
JP2023078173A5 (enExample)
JP2024149687A5 (enExample)
JP2024099585A5 (enExample)